Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.
about
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parametersEvaluation of current cancer immunotherapy: hemato-oncologyValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationAbacavir-reactive memory T cells are present in drug naïve individualsMinimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapiesMeeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshopThe simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.The immuno-oncology framework: Enabling a new era of cancer therapy.Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring.Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring.Overnight resting of PBMC changes functional signatures of antigen specific T- cell responses: impact for immune monitoring within clinical trials.Report from the second cytomegalovirus and immunosenescence workshop.A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative.Neonatal regulatory T cells have reduced capacity to suppress dendritic cell function.Trial watch: Peptide vaccines in cancer therapyHuman papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.Harmonization of immune biomarker assays for clinical studies.The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization.Immune responses to cancer: are they potential biomarkers of prognosis?DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up.Harmonization of the intracellular cytokine staining assay.The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.Immuno-oncology combinations: raising the tail of the survival curve.A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.Structured reporting of T cell assay results.
P2860
Q24615872-A46B3D05-64C6-4E62-9057-C621A5A61795Q27006179-E38AA4E1-ABBF-4892-9364-3E3AC1A6F93FQ28075719-213542AB-F96A-4989-965B-389AA862A643Q28543405-0E2D628B-F0A1-4EAC-AF17-46782969F689Q28596281-B9672252-E4EB-4597-8E83-722966B3B76CQ28743008-1CEA0C55-361F-4059-9126-EF1F9176CF1DQ30528191-C5BBAA2A-8762-4ED1-9D57-5BA7BA5B1DD0Q30620607-BC97C0EB-3F79-4FCB-9FB6-89CA9C6BE399Q33876878-1B70D2E9-7995-436A-AFCD-93196535D199Q33938435-651786AC-8844-4D9C-A0C4-EDC18FFA99BCQ34284462-CF7252B5-26B1-4434-A43C-90291F108136Q34522294-28074281-1E2E-476F-8DF0-C94B565E60A2Q34530756-228B49C9-7755-4FBE-892D-91E4E272AE3FQ35022675-D22E0E6C-AB9F-47EA-97D7-F31700B5A08CQ35568719-D0FC546F-5655-4A9B-912A-DB145DFF63BBQ36189261-6AF65A4A-4D73-4A70-9713-20454CB3F16BQ36318352-E7685092-92FF-4F6C-80E0-8A4A3A63CB54Q36337433-F9A11EBF-6A80-4FFB-826E-4B71A02452C3Q36476100-7EE21D9B-B43A-4A7D-852C-FD25AD236A52Q37593170-C67CA23F-886B-4B88-BA11-8DDB5B51461DQ37954593-834A72DF-F57E-4841-ABD3-ADDF0AF3919FQ40282470-7B75D330-6A33-4106-B361-720805EA92FCQ40778413-A9750C63-3D55-457E-B097-8FB0F03E417FQ41325762-5100281D-CBE3-43B5-9901-8D49B6742737Q41550516-7AEF7C5E-415B-4045-AB99-CCE7278C306EQ41842804-3DD5FB50-0F3F-4E6A-BA0C-E61F8221D667Q42207308-E3F78BE1-0734-4769-A5AA-C9ED673C1BC7Q42255546-8A537AEC-97AD-4EA1-9CE6-DB0C62965DF9Q42421273-20F11A1B-0350-4079-BC34-26130C104018Q42851663-F1D84A5A-FA3B-4102-BF11-E3E9B7657A38Q43081521-2FFF07E6-3743-4F56-94D7-4614CEE57220
P2860
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Minimal information about T ce ...... ologists in cancer and beyond.
@ast
Minimal information about T ce ...... ologists in cancer and beyond.
@en
type
label
Minimal information about T ce ...... ologists in cancer and beyond.
@ast
Minimal information about T ce ...... ologists in cancer and beyond.
@en
prefLabel
Minimal information about T ce ...... ologists in cancer and beyond.
@ast
Minimal information about T ce ...... ologists in cancer and beyond.
@en
P2093
P2860
P1476
Minimal information about T ce ...... ologists in cancer and beyond.
@en
P2093
C J M Melief
C M Britten
H I Levitsky
H T Maecker
J O'Donnell-Tormey
P2860
P2888
P356
10.1007/S00262-010-0940-Z
P577
2010-11-16T00:00:00Z
P5875
P6179
1037517799